|
|
| Line 1: |
Line 1: |
| '''Coartem''' is the commercial name of [[artemether]]–[[lumefantrine]], a drug combination effective in treating [[malaria]], developed by the Ciba and Sandoz laboratories in 1996. Subsequent to their merger, the patent now belongs to [[Novartis]]. It was added to the [[WHO essential drug list]],<ref>[http://www.sahealthinfo.org/malaria/faq.htm] An FAQ on health-based issues, particularly those concerning Southern Africa</ref> showing a success rate above 95 %. To help fight [[malaria]], which kills approximately 3 million people every year, mostly in Third-World countries, the WHO and Novartis concluded an agreement to help manufacture and sell the drug at lower costs in countries where the average income rarely exceeds two dollars a day. An audit found that Novartis lost 80 cents for every dose sold.<ref>[http://www.medicalprogresstoday.com/spotlight/spotlight_indarchive.php?id=821] Article from Medical Progress Today</ref> The expected number of orders for 2006 was 100 million, but due to local difficulties, namely the lack of a proper health infrastructure in Third World countries, the number of doses actually sold will be far less than that.<ref>[http://www.lemonde.fr/web/article/0,1-0@2-3232,36-765175,0.html] by Daniel Vasella, chairman and CEO of Novartis, article published in Le Monde, April 26th, 2006</ref>
| | #REDIRECT [[Artemether/lumefantrine]] |
| | |
| A dose of Coartem now costs 55 cents for a child up to age 3.<ref>[http://www.nytimes.com/2006/06/28/world/africa/28malaria.html?hp&ex=1151553600&en=815033efe8ce8f91&ei=5094&partner=homepage]
| |
| New York Times article on new tactis to fight malaria, June 28th 2006</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| | |
| {{Antimalarials}}
| |
| | |
| | |
| {{antimicrobial-stub}}
| |
| [[Category:Antimalarial agents]]
| |
| | |
| [[fr:Coartem]]
| |
| {{WikiDoc Help Menu}}
| |